Sort by

Send to

Choose Destination

Search results

Items: 3


Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.

Pejchinovski M, Siwy J, Metzger J, Dakna M, Mischak H, Klein J, Jankowski V, Bae KT, Chapman AB, Kistler AD.

Nephrol Dial Transplant. 2017 Mar 1;32(3):487-497. doi: 10.1093/ndt/gfw243.


Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.

Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.

PLoS One. 2013;8(1):e53016. doi: 10.1371/journal.pone.0053016. Epub 2013 Jan 10. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/9281c713-d253-4a1a-8255-92e691e77a24.


A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.

Kistler AD, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wüthrich RP, Serra AL.

PLoS One. 2011;6(6):e20534. doi: 10.1371/journal.pone.0020534. Epub 2011 Jun 15.

Supplemental Content

Loading ...
Support Center